CA
NZ
UK
AU
IND
US
…
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Aurinia Pharmaceuticals commercializes therapies for autoimmune kidney disease; its lead product voclosporin (Lupkynis) is approved for lupus nephritis. Long-term growth may be supported by wider clinical adoption, label expansions, international rollout and pipeline advancement; investors may find it attractive as a commercial-stage autoimmune drug developer addressing an unmet need.
Key risks include dependence on a single approved product with uncertain uptake, competition from other therapies, regulatory or clinical setbacks for new indications, and possible need for additional financing.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 114.16M | 7.45M | -77.47M | -106.35M | -180.21M |
| Net income | 287.20M | 5.75M | -78.02M | -108.18M | -180.97M |
| Selling general administrative | 101.79M | 157.93M | 195.04M | 196.37M | 171.44M |
| Selling and marketing expenses | - | 14.09M | - | - | - |
| Gross profit | 250.39M | 206.88M | 161.37M | 128.37M | 44.51M |
| Reconciled depreciation | 19.45M | 19.45M | 6.92M | 2.71M | 2.76M |
| Ebit | 118.49M | 12.28M | -74.69M | -114.18M | -180.74M |
| Ebitda | 127.76M | 31.73M | -63.05M | -111.47M | -178.64M |
| Depreciation and amortization | 9.27M | 19.45M | 11.65M | 2.71M | 2.10M |
| Non operating income net other | - | - | - | - | 0.53M |
| Operating income | 104.91M | -4.69M | -91.69M | -111.47M | -180.74M |
| Other operating expenses | 178.14M | 239.82M | 267.20M | 245.50M | 226.34M |
| Interest expense | 4.33M | 4.83M | 2.77M | 5.12M | 0.53M |
| Tax provision | -173.04M | 1.70M | 0.95M | 1.83M | 0.76M |
| Interest income | 13.57M | 16.97M | 15.34M | 5.12M | 0.53M |
| Net interest income | 9.24M | 12.13M | 13.87M | 5.12M | 0.53M |
| Income tax expense | -173.04M | 1.70M | 0.55M | 1.83M | 0.76M |
| Total revenue | 283.06M | 235.13M | 175.51M | 134.03M | 45.60M |
| Total operating expenses | 145.48M | 211.57M | 253.06M | 239.84M | 225.25M |
| Cost of revenue | 32.66M | 28.25M | 14.15M | 5.66M | 1.09M |
| Total other income expense net | 9.24M | 12.13M | 14.22M | 5.12M | 0.53M |
| Net income from continuing ops | 287.20M | 5.75M | -77.19M | -108.18M | -180.97M |
| Net income applicable to common shares | - | - | - | -108.18M | -180.97M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 751.59M | 550.64M | 548.06M | 470.86M | 543.37M |
| Intangible assets | 3.76M | 4.36M | 4.98M | 6.42M | 8.40M |
| Other current assets | 6.83M | 12.35M | 10.52M | 1.33M | 0.80M |
| Total liab | 170.26M | 173.17M | 170.11M | 65.42M | 64.28M |
| Total stockholder equity | 581.33M | 377.48M | 377.95M | 405.44M | 479.09M |
| Other current liab | 69.10M | 66.50M | 52.45M | 38.94M | 4.64M |
| Common stock | 1120.04M | 1187.70M | 1200.22M | 1185.31M | 1177.05M |
| Capital stock | 1120.04M | 1187.70M | 1200.22M | 1185.31M | 1177.05M |
| Retained earnings | -649.37M | -936.57M | -942.32M | -864.30M | -756.12M |
| Other liab | - | - | - | 12.17M | 15.95M |
| Other assets | - | - | - | 13.34M | 11.84M |
| Cash | 80.21M | 83.43M | 48.88M | 94.17M | 231.90M |
| Total current liabilities | 93.72M | 97.76M | 77.19M | 46.11M | 40.65M |
| Current deferred revenue | 3.72M | 11.00M | 4.81M | 3.15M | 31.07M |
| Net debt | -5.40M | -4.06M | 48.73M | -86.08M | -223.16M |
| Short term debt | 17.59M | 15.07M | 15.60M | 0.94M | 1.06M |
| Short long term debt total | 74.81M | 79.37M | 97.61M | 8.09M | 8.74M |
| Other stockholder equity | 111.26M | 127.00M | 120.79M | 85.49M | 59.01M |
| Property plant equipment | - | - | - | 8.56M | 9.80M |
| Total current assets | 491.97M | 446.60M | 424.80M | 442.54M | 513.32M |
| Long term investments | - | 0.00M | 0.20M | - | 0.00M |
| Net tangible assets | - | - | - | 399.01M | 470.69M |
| Short term investments | 317.78M | 275.04M | 301.61M | 295.22M | 234.18M |
| Net receivables | 41.45M | 36.54M | 24.09M | 13.48M | 15.41M |
| Inventory | 45.69M | 39.23M | 39.70M | 24.75M | 19.33M |
| Accounts payable | 3.31M | 5.19M | 4.33M | 3.09M | 3.88M |
| Accumulated other comprehensive income | -0.60M | -0.65M | -0.73M | -1.06M | -0.85M |
| Common stock total equity | - | - | - | - | 1177.05M |
| Retained earnings total equity | - | - | - | - | -756.12M |
| Non currrent assets other | 0.09M | 0.82M | 1.52M | 13.34M | 11.84M |
| Non current assets total | 259.62M | 104.05M | 123.26M | 28.32M | 30.04M |
| Capital lease obligations | 74.81M | 79.37M | 97.61M | 8.09M | 8.74M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -32.52M | 39.26M | -3.47M | -60.63M | -84.53M |
| Change to liabilities | - | - | - | 3.75M | 4.08M |
| Total cashflows from investing activities | -32.77M | 39.26M | -6.71M | -60.63M | -103.87M |
| Net borrowings | -13.14M | -11.99M | -10.03M | - | - |
| Total cash from financing activities | -106.11M | -49.09M | -5.13M | 2.43M | 221.11M |
| Change to operating activities | - | - | - | -3.42M | -4.65M |
| Net income | 287.20M | 5.75M | -78.02M | -108.18M | -180.97M |
| Change in cash | -3.22M | 34.56M | -45.30M | -137.73M | -40.45M |
| Begin period cash flow | 83.43M | 48.88M | 94.17M | 231.90M | 272.35M |
| End period cash flow | 80.21M | 83.43M | 48.88M | 94.17M | 231.90M |
| Total cash from operating activities | 135.66M | 44.39M | -33.46M | -79.53M | -157.69M |
| Issuance of capital stock | - | - | 0.00M | 0.00M | 196.74M |
| Depreciation | 9.27M | 19.45M | 11.65M | 2.71M | 2.76M |
| Other cashflows from investing activities | - | -0.04M | -11.86M | -0.66M | -11.84M |
| Change to inventory | -6.46M | 0.48M | -15.87M | -9.07M | -5.64M |
| Change to account receivables | -4.91M | -12.46M | -10.61M | 1.93M | -15.41M |
| Sale purchase of stock | -98.16M | -40.24M | 0.00M | - | 221.11M |
| Other cashflows from financing activities | -9.76M | 3.14M | 4.89M | -60.63M | 24.37M |
| Change to netincome | - | - | - | 32.76M | 42.15M |
| Capital expenditures | 0.25M | 0.28M | 0.72M | 0.29M | 1.50M |
| Change receivables | - | - | - | - | -15.41M |
| Cash flows other operating | - | - | - | - | 5.35M |
| Cash and cash equivalents changes | - | - | - | - | -40.45M |
| Change in working capital | -8.78M | 5.45M | -5.61M | -6.82M | -21.63M |
| Stock based compensation | 14.68M | 31.60M | 45.31M | 32.30M | 31.24M |
| Other non cash items | 9.48M | -17.85M | -6.79M | 0.46M | 10.90M |
| Free cash flow | 135.41M | 44.11M | -34.18M | -79.82M | -159.19M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AUPH Aurinia Pharmaceuticals Inc |
0.11 0.64% |
17.36 | 7.64 | 23.04 | 7.43 | 3.65 | 6.36 | 13.04 |
| NVO Novo Nordisk A/S |
-0.38 0.98% |
38.29 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
8.66 1.66% |
529.69 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-2.83 0.35% |
813.27 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
790.15 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
#140, 14315 ? 118 Avenue, Edmonton, AB, Canada, T5L 4S6
250 744 2487
128
| Name | Title | Year Born |
|---|---|---|
| Mr. Peter S. Greenleaf M.B.A. | Pres, CEO & Director | 1970 |
| Mr. Joseph M. Miller CPA | Chief Financial Officer | 1974 |
| Mr. Matthew Maxwell Donley M.B.A. | Exec. VP of Operations & Strategy | 1969 |
| Mr. Stephen P. Robertson | Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer | 1982 |
| Ms. DeDe Sheel | VP of Investor Relation | NA |
| Mr. Chris Hays | VP of Marketing | NA |
| Mr. Fran Lynch | VP of Sales | NA |
| Mr. Michael R. Martin | Chief Bus. Officer | 1972 |
| Ms. Sue Evans | Head of Regulatory Affairs | NA |
| Mr. Scott Habig | Chief Commercial Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.02%
Communication Services
-0.63%
Consumer Cyclical
-0.11%
Consumer Defensive
-0.45%
Energy
+0.39%
Financial Services
-0.10%
Financials
-0.81%
Healthcare
+1.03%
Industrials
+0.32%
Real Estate
-0.31%
Technology
+0.59%
Utilities
-0.18%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...